N⁶-(2-phenylethyl)-2-<(phenylethyl)amino>adenosine | 120524-43-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N⁶-(2-phenylethyl)-2-<(phenylethyl)amino>adenosine
• 英文别名: N⁶-(2''-phenylethyl)-2-[(2''-phenylethyl)amino]adenosine；2,6-bis(2-phenylethylamino)purine riboside；N⁶-phenylethyladenosine；(2R,3R,4S,5R)-2-[2,6-bis(2-phenylethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 120524-43-8
• 化学式: C₂₆H₃₀N₆O₄
• 分子量: 490.562
• InChiKey: ZQMZXBHWVOHWIF-PTGPVQHPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  138
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  6-氯鸟嘌呤核苷 在 copper(l) iodide 、 碘 、 N,N-二异丙基乙胺 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙二醇甲醚 为溶剂， 反应 42.5h， 生成 N⁶-(2-phenylethyl)-2-<(phenylethyl)amino>adenosine
  参考文献：
  名称：

  Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine

  摘要：

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.

  DOI：

  10.1021/jm000287a

文献信息

• C2,N6-Disubstituted adenosines: synthesis and structure-activity relationships
  作者：Bharat K. Trivedi、Robert F. Bruns

  DOI：10.1021/jm00128a002

  日期：1989.8

  Extracellular adenosine receptors have been divided into two major subtypes, called A1 and A2. Substitution of the adenosine molecule with appropriate groups at C2 or N6 is known to impart selectivity for the A2 receptor over the A1 receptor. In the present study, we investigated whether substitution at both C2 and N6 would have additive effects on the A2/A1 affinity ratio, thereby providing compounds

  细胞外腺苷受体已被分为两种主要的亚型，称为A1和A2。已知在C2或N6处具有适当基团的腺苷分子的取代赋予A2受体相对于A1受体的选择性。在本研究中，我们研究了在C2和N6处取代是否会对A2 / A1亲和力比产生累加效应，从而为化合物提供比目前可用的试剂更高的A2选择性。令人失望的是，仅当在N6处有一个A1选择性基团时，可加性似乎才成立。例如，A1-选择性激动剂N6-环戊基腺苷的2-（苯氨基）取代导致对A2受体的选择性变化了70倍，但对A2-选择性激动剂N6- [2- （3，
• A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
  作者：Andrea Spinaci、Michela Buccioni、Diego Dal Ben、Federica Maggi、Gabriella Marucci、Beatrice Francucci、Giorgio Santoni、Catia Lambertucci、Rosaria Volpini

  DOI：10.3390/ph15020164

  日期：——

  more pronounced effects with respect to the ones elicited by the reference full agonist Cl-IB-MECA. In particular, the N6-(2,2-diphenylethyl)-2-phenylethynylAdo (12: GI50 = 14 µM, TGI = 29 µM, and LC50 = 59 µM) showed the highest activity proving to be a potential antitumor agent. The cytostatic effect of both A3AR agonist (Cl-IB-MECA) and antagonists (12 and other newly synthesized compounds) confirm

  A3 腺苷受体 (AR) 在多种癌细胞类型中的过表达使其成为肿瘤诊断和治疗的有吸引力的靶标。因此，在寻找新的 A3AR 配体时，合成了一系列新的 2,N6-二取代腺苷 (Ados)，并在 AR 的放射性配体结合和功能测定中进行了测试。发现在 N6 位带有 2-苯乙氨基的衍生物比相应的 N6-(2,2-二苯乙基) 类似物具有更高的 A3AR 亲和力和选择性。在 cAMP 积累试验中，发现 2-Chloro-N6-phenylethylAdo (15) 是一种有效的全 A3AR 激动剂，Ki 为 0.024 nM，EC50 为 14 nM。与 15 不同，其他配体表现为 A3AR 拮抗剂，其浓度依赖性地降低细胞生长并对前列腺癌细胞系 PC3 发挥细胞抑制活性，显示出与参考完全激动剂 Cl-IB-MECA 引发的效果相当甚至更显着的效果。特别是 N6-(2,2-diphenylethyl)-2-phenylethynylAdo
• The synthesis of N 2,N 6-substituted diaminopurine ribosides
  作者：N. A. Golubeva、A. V. Shipitsyn

  DOI：10.1134/s1068162007060052

  日期：2007.11

  A series of new 2,6-substituted diaminopurine riboside derivatives were synthesized by activation of protected xantosine with sulfonyl chlorides followed by treatment with various amines. The relationship between the reactivity of intermediates and the nature of the activating agents was studied.
• Adenosine Analogues as Inhibitors of <i>Trypanosoma </i><i>b</i><i>rucei </i>Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine
  作者：Jerome C. Bressi、Jungwoo Choe、Melinda T. Hough、Frederick S. Buckner、Wesley C. Van Voorhis、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm000287a

  日期：2000.11.1

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.